P4640 - Temporal Trends and Regional Disparities in the Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) From 1980 to 2021: An Analysis of GBD Study 2021

Muhammad Tayyab Anwar, MD¹, Muhammad Shahzil, MD², Liaqat Maryyam, MD³, Wania Rehman, MBBS³, Muhammad Talha Shaukat, MBBS³, Rija Siddiqui, MBBS⁴, Muhammad Shahzaib, MBBS³, Aqeeb Ur Rehman, MD³, Aleenah Mohsin, MD⁵, Muhammad Imtanan Fazal, MD⁶, Zunaira Amjad, MBBS⁶, Ali Mohsin, MBBS⁷, Sibgha Farooq, MBBS^8
1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; ²Penn State Health Milton S. Hershey Medical Center, Hershey, PA; ³King Edward Medical University, Lahore, Punjab, Pakistan; ⁴Ziauddin University, Karachi, Sindh, Pakistan; ⁵Brown University / Rhode Island Hospital, Providence, RI; ⁶Services Institute of Medical Sciences, Lahore, Punjab, Pakistan; ⁷Shalamar Institute of Health Sciences, Lahore, Punjab, Pakistan; ⁸University of Health Sciences, Lahore, Punjab, Pakistan

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) previously known as Non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of liver- related morbidity worldwide. As its prevalence continues to rise globally, understanding the epidemiology and trends of NAFLD becomes crucial for effective public health strategies, early diagnosis, and timely interventions.

Methods: This study utilized data on non-alcoholic fatty liver disease (NAFLD) from the Global Burden of Diseases (GBD) database, including age-standardized death rates (ASDR), Years of Lost Life (YLL), and disability-adjusted life years (DALYs). The data were
stratified by continent, socio-demographic index (SDI), and World Bank income groups. The Joinpoint Regression Program was used to assess trends and calculate average annual percentage changes (AAPC).

Results: Globally, ASDR for MASLD (NAFLD) demonstrated a steady trend from 1980 to 2021. In 1980, the ASDR was 1.53 (95% UI: 1.15-2.00), and it increased slightly to 1.62 (AAPC: 0.13; 95% CI: 0.11-0.15) by 2021. A significant change in the ASDR was shown from 1988 to 1995 with an annual percentage change (APC) of 0.87 (95% CI: 0.70-1.26). The global DALYs rate for NAFLD increased from 40.20 (95% UI: 30.73-52.23) in 1990 to 42.63 (AAPC: 0.18; 95% CI: 0.15-0.21) in 2021. Additionally, the age-standardized YLL due to NAFLD increased from 40.63(95% UI: 31.14-53.26) in 1980 to 41.89 in 2021 (AAPC: 0.08; 95% CI: 0.06-0.10). In continent-wise analysis, Africa exhibited the highest ASDRs, with an AAPC of 0.27% (95% CI: 0.24-0.30%) from 1980 to 2021 while Asia had the lowest ASDRs, with an AAPC of -0.07% (95% CI: -0.09 to -0.05%). America showed the highest increasing trend with an AAPC of 0.76% (95% CI: 0.73-0.78%) while Europe experienced varied trends, with an overall AAPC of 0.35% (95% CI: 0.30-0.40%). Low income level countries and low SDI regions had the highest ASDRs.

Discussion: MASLD (previously NAFLD) continues to pose a significant global health challenge, often associated with various metabolic disorders. Africa reported the highest ASDRs, likely influenced by limited healthcare access while America exhibited the most notable increase in ASDR, reflecting the impact of the obesity epidemic. These findings underscore the interplay of socioeconomic factors and lifestyle choices and the need for targeted health interventions to reduce the disease burden.



Disclosures:


Muhammad Tayyab Anwar, MD¹, Muhammad Shahzil, MD², Liaqat Maryyam, MD³, Wania Rehman, MBBS³, Muhammad Talha Shaukat, MBBS³, Rija Siddiqui, MBBS⁴, Muhammad Shahzaib, MBBS³, Aqeeb Ur Rehman, MD³, Aleenah Mohsin, MD⁵, Muhammad Imtanan Fazal, MD⁶, Zunaira Amjad, MBBS⁶, Ali Mohsin, MBBS⁷, Sibgha Farooq, MBBS⁸. P4640 - Temporal Trends and Regional Disparities in the Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) From 1980 to 2021: An Analysis of GBD Study 2021, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.